This HTML5 document contains 60 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n13http://linked.opendata.cz/resource/drugbank/drug/DB01544/identifier/pubchem-compound/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n6http://linked.opendata.cz/resource/mesh/concept/
n16http://linked.opendata.cz/resource/drugbank/drug/DB01544/identifier/kegg-drug/
n14http://linked.opendata.cz/resource/drugbank/drug/DB01544/identifier/pubchem-substance/
n15http://linked.opendata.cz/resource/drugbank/drug/DB01544/identifier/drugbank/
n9http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n18http://linked.opendata.cz/resource/drugbank/drug/DB01544/identifier/chemspider/
n21http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n5http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
n19http://linked.opendata.cz/resource/drugbank/drug/DB01544/identifier/pharmgkb/
n20http://linked.opendata.cz/resource/drugbank/drug/DB01544/identifier/wikipedia/
xsdhhttp://www.w3.org/2001/XMLSchema#
n11http://linked.opendata.cz/resource/atc/
n17http://linked.opendata.cz/resource/drugbank/drug/DB01544/identifier/bindingdb/
n10http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01544
rdf:type
n3:Drug
n3:description
A benzodiazepine with pharmacologic actions similar to those of diazepam that can cause anterograde amnesia. Some reports indicate that it is used as a date rape drug and suggest that it may precipitate violent behavior. The United States Government has banned the importation of this drug. [PubChem]
n3:generalReferences
# Rickels K: The clinical use of hypnotics: indications for use and the need for a variety of hypnotics. Acta Psychiatr Scand Suppl. 1986;332:132-41. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/2883820 # Robertson MD, Drummer OH: Postmortem drug metabolism by bacteria. J Forensic Sci. 1995 May;40(3):382-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/7782744 # Oelschlager H: [Chemical and pharmacologic aspects of benzodiazepines] Schweiz Rundsch Med Prax. 1989 Jul 4;78(27-28):766-72. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/2570451 # Usami N, Yamamoto T, Shintani S, Ishikura S, Higaki Y, Katagiri Y, Hara A: Substrate specificity of human 3(20)alpha-hydroxysteroid dehydrogenase for neurosteroids and its inhibition by benzodiazepines. Biol Pharm Bull. 2002 Apr;25(4):441-5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11995921 # Tokunaga S, Takeda Y, Shinomiya K, Hirase M, Kamei C: Effects of some H1-antagonists on the sleep-wake cycle in sleep-disturbed rats. J Pharmacol Sci. 2007 Feb;103(2):201-6. Epub 2007 Feb 8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17287588
n3:group
approved illicit
n3:halfLife
18-26 hours
n3:indication
For short-term treatment of severe insomnias, that are not responsive to other hypnotics.
owl:sameAs
n9:DB01544 n21:DB01544
dcterms:title
Flunitrazepam
adms:identifier
n13:3380 n14:46504553 n15:DB01544 n16:D01230 n17:25878 n18:3263 n19:PA164781320 n20:Flunitrazepam
n3:mechanismOfAction
Benzodiazepines bind nonspecifically to benzodiazepine receptors BNZ1, which mediates sleep, and BNZ2, which affects affects muscle relaxation, anticonvulsant activity, motor coordination, and memory. As benzodiazepine receptors are thought to be coupled to gamma-aminobutyric acid-A (GABAA) receptors, this enhances the effects of GABA by increasing GABA affinity for the GABA receptor. Binding of the inhibitory neurotransmitter GABA to the site opens the chloride channel, resulting in a hyperpolarized cell membrane that prevents further excitation of the cell.
n3:synonym
Flunitrazepamum Rohypnol
n3:toxicity
Symptoms of overdose include confusion, coma, impaired coordination, sleepiness, and slowed reaction time.
n3:foodInteraction
Avoid excessive quantities of coffee or tea (Caffeine). Avoid alcohol. Avoid taking with grapefruit juice. Take with food.
n3:synthesisReference
Kariss, J. and Newmark, H.L.; U.S. Patent 3,116,203; December 31, 1963; assigned to Hoffmann-la Roche Inc.
 Kariss, J. and Newmark, H.L.; US. Patent 3,123,529; March 3,1964; assigned to Hoffmann-La Roche Inc. 
Keiler, O., Steiger, N. and Sternbach, L.H.; U.S. Patent 3,203,990; August 31, 1965; assigned to Hoffmann-La Roche Inc.
n5:hasConcept
n6:M0008590
n3:IUPAC-Name
n4:271B53DF-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B53E5-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B53E4-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B53E1-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B53E2-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B53E3-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B53DD-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B53DB-363D-11E5-9242-09173F13E4C5 n4:271B53DE-363D-11E5-9242-09173F13E4C5 n4:271B53F5-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B53DC-363D-11E5-9242-09173F13E4C5
n10:hasATCCode
n11:N05CD03
n3:H-Bond-Acceptor-Count
n4:271B53EB-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B53EC-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B53E6-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B53E7-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B53E9-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B53E8-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B53EA-363D-11E5-9242-09173F13E4C5
n3:absorption
50% (suppository) and 64-77% (oral)
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
1622-62-4
n3:category
n3:Bioavailability
n4:271B53F0-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B53F2-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B53F3-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B53F4-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B53EF-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B53EE-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B53F1-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B53E0-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B53ED-363D-11E5-9242-09173F13E4C5